Biography for Eric Palmer
Eric Palmer, Senior Editor
Eric Palmer is a business and technology journalist with more than three decades of prize-winning experience as a reporter and editor with daily, weekly, monthly and online publications. He was healthcare reporter for The Kansas City Star before becoming deputy business editor for the daily newspaper. He spent eight years as editor of The Kansas City Business Journal, which had a strong emphasis on the healthcare industry. On the personal side, he is an avid fly fisherman, cooks and collects wine, and likes to travel with his family. Eric is based in Kansas City and can be reached at firstname.lastname@example.org.
Articles by Eric Palmer
NewLink Genetics and its new partner Merck have gotten a $30 million grant from the U.S. government to help with manufacturing and development of the Ebola vaccine the two are working on.
Last year, India's Cipla forked over $500 million to get complete ownership of South Africa's Cipla Medpro. A new contract from the South African government for antiretroviral drugs sheds some light on the potential motivation for more than doubling its original offer to get the whole company.
Companies in Egypt have been advertising Indian-made versions of Gilead Sciences' hepatitis C cure Sovaldi for sale. The problem is, none of the 7 drugmakers that were granted the right to produce the drug, 6 of them Indian companies, have gotten past development with the product. That suggests that whatever is being sold in Egypt is not really generic Sovaldi.
Japan's Fujifilm has completed the purchase of not quite 50% of vaccine specialist Kalon Biotherapeutics, making it a key player in the U.S. pandemic defenses.
Bayer Healthcare manufactures Xofigo, its targeted agent for fighting prostate cancer that has spread to the bone, at a plant in Norway. Now it says Cardinal Health, which exclusively distributes the product in the U.S. and Canada, will build a facility in Indianapolis that will be used only for manufacturing Xofigo.
German drugmaker Fresenius Kabi's U.S. operation has completed the recall of half a million vials of drugs started more than two years ago because the glass had fractures and might contain particles.
Workers at an Onyx Pharmaceuticals facility in South San Francisco filed out of the building and into a parking lot Wednesday afternoon after employees reported smelling gas.
The latest FDA visit to Hovione's plant in Loures, Portugal, for a preapproval inspection resulted in a Form 483 with three observations.
Drugmaker Pozen says its API supplier has done everything the FDA asked after noting issues in an April plant inspection and the company resubmitted its application in July. But the FDA's compliance division has been too busy to get back to the plant and see for itself, and so the agency has sent Pozen a second CRL with "identical wording."
A federal indictment alleges that the now-defunct New England Compounding Center reaped millions of dollars by cutting corners in the manufacture of what were supposed to be sterile drugs, falsifying records, using expired ingredients and lying to clients about their safety.